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(TIMI 3) was lower in patients with CTO. In-hospital as well as 12-months mortality
was significantly higher in patients with CTO. After multivariate adjustment for
differences in baseline characteristics, presence of chronic total occlusion remained
significantly associated with higher 12-months mortality (relative risk = 1.42, 95%CI
= 1.01-2.00, p=0.047).
Conclusion: Chronic total occlusion(s) found in patients with 3-vessels disease and
NSTEMI treated by primary PCI are associated with worse 12-months mortality.
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Background: We prospectively studied whether specific EKG patterns predicted
decreased DTB times in STEMI. Select lead group involvement allows localizing areas
of infarcted tissue and reciprocal changes and ST-segment morphology help in STEMI
recognition. Certain ischemic patterns as well presence or absence of reciprocal ST-
depression (RSTD) may result in quicker interpretation with earlier diagnosis and
shorter DTB.
Methods: EKG’s of 209 STEMI pts treated with primary PCI at a single urban center
were reviewed for RSTD, patterns of localization, presence of multiple ischemic
distributions and amplitude of STD. These changes were compared with mean DTB
as well as door to catheterization (DTC) times.
Results: Involvement of >1 ischemic distribution resulted in earlier DTB (82 vs 106
mins, p<0.05) (Graph 1). Presence of anterior MI was associated with delayed DTB,
OR for achieving DTB<90 mins, 0.50 [0.27-0.94]. Pts with DTB<90 mins
demonstrated greater mean STE than those with DTB>90 mins, 3.0 +/- 1.5 vs 2.4 +/-
1.4, (p<0.01), were more likely to have had inferior/posterior MI (67.2% vs 45.1%,
p=0.01), as well as RSTD (71.6% vs 43.7%, p<0.01). When adjusted for other
variables, RSTD remained the strongest predictor of DTB<90 minutes, HR 3.4 [1.76-
6.98] (p=0.001).
Conclusion: The number of EKG leads with STD and specifically, the presence of
RSTD and >1 ischemic distribution, were associated with shorter DTB times and
opening of infarct vessel faster. Striving for shorter DTB times in patients with anterior
MI through timely ECG interpretation is an important goal. The data suggests education
regarding localization of STEMI and a rapid reaction to all STD should be reinforced
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Background: B-type natriuretic peptide (BNP) levels have been associated with
increased mortality and development of heart failure in acute coronary syndromes.
Whether this holds true after adjusting for other prognostic variables such as reduced
left ventricular ejection fraction is unknown. We therefore investigated 3-year outcomes
as function of BNP levels in a large cohort of patients with acute ST-elevation
myocardial infarction (STEMI) undergoing primary PCI.
Methods: A total of 1089 STEMI patients enrolled in the HORIZONS-AMI trial had
baseline BNP levels measured in the emergency room as part of the study protocol.
We assessed all-cause and cardiac mortality, non-fatal MI, TVR, stent thrombosis,
ischemic stroke, non-CABG related major bleeding and net adverse clinical events
(NACE = MACE or major non-CABG bleeding) as a function of admission BNP.
Results: Higher tertiles of admission BNP were strongly associated with the 3-year
rates of cardiac and all-cause mortality, ischemic stroke, major non-CABG bleeding,
blood transfusions, MACE and NACE (Table). Conversely, BNP was not significantly
associated with reinfarction, TVR or stent thrombosis (Table). After multivariable
analysis adjusting for age, cardiovascular risk factors, hemoglobin concentration, eGFR
and LVEF, BNP was not an independent predictor of MACE (HR 1.05; p=0.26) or all-
cause mortality (HR 1.19; p=0.07) and showed only a modest association with cardiac
death (HR 1.26; p=0.04).
Conclusion: In patients with STEMI undergoing primary PCI, high baseline BNP was
associated with numerous adverse clinical outcomes, principally major bleeding,
ischemic stroke and cardiac death. After multivariable adjustment for measured
confounders, higher BNP concentrations were not significantly associated with MACE
or all-cause mortality after 3-years, but remained weakly correlated with cardiac death.a
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Background: The impact of a chronic total occlusion (CTO) in a non infarct related
coronary artery (IRA) in STEMI patients was shown to be a strong predictor for
mortality. We hypothesized that certain combinations of the CTO and IRA are
associated with increased mortality.
Methods: Between 1997-2008, we admitted 533 STEMI patients with a CTO in a non-
IRA. Survival analysis to 5-year follow-up was performed. Cox regression was used
to calculate hazard ratios. The combination with the lowest mortality was used as the
reference category.
Results: In figure 1 the combined effect of the CTO and IRA are shown. Interestingly,
combinations which constitute the LAD as an IRA or as a CTO had significantly higher
mortality rates in contrast to combinations which contained the RCA together with the
RCX. After multivariate adjustment, the following combinations kept its predictive
value: culprit in LAD with CTO in RCA (HR:2.2,p=0.01) and culprit in RCX with
CTO in LAD (HR:2.3,p=0.03). The combination: culprit in LAD with CTO in RCX,
was borderline significant (HR:1.9,p=0.055).
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Conclusion: STEMI patients with a CTO have an increased mortality rate. Certain
combinations of the CTO and the IRA seem to determine mortality even further,
especially when the LAD is involved.
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Background: Data from randomized trials and meta-analyses suggest that routine
manual thrombus aspiration (TA) and glycoprotein inhibitor (GPI) use during PPCI
for STEMI is associated with improved markers of reperfusion and reduced MACE at
1-year follow-up. However, real-world data is lacking, and debate continues over
whether a strategy of selective TA in particular patient subgroups (e.g. large thrombus
burden, short ischemic times) might be more appropriate; concerns over bleeding may
also limit uptake of GPI.
Methods: Consecutive patients attending a single center undergoing PPCI for STEMI
between September 2008 and December 2010 were included in this analysis. All
patients received aspirin 300mg and clopidogrel 600mg at point of STEMI diagnosis
in the community; use of TA and/or GPI during PPCI were at operator discretion.
Demographic data and clinical outcomes were obtained by interrogation of local and
national databases.
Results: 915 patients (mean age 64.6 +/- 12.6 years, 76.0% male) were included;
overall inhospital mortality was 3.2% (29/915), with 30-day and 1-year mortality of
4.0% (37/915) and 9.5% (65/681) respectively. There was no significant 1-year survival
advantage in patients receiving TA (55.7%) compared with those who did not (91.8%
vs 88.3%; p=0.18). GPI use (44.3%) did not confer survival advantage either alone or
when considered with TA for the whole population. However, in patients presenting
within 3 hours of onset of symptoms, both TA (5.4% vs 12.0%; p=0.04) and GPI use
(2.0% vs 15.2%; p=0.002) were associated with reduced mortality at 1 year.
Conclusion: In an unselected real-world population undergoing PPCI for STEMI, only
patients presenting with a short ischemic time (within 3 hours of pain onset) derived
1-year survival benefit from TA or GPI. In contrast to published data, these findings
suggest that routine TA/GPI use in this setting may not be universally beneficial.
Further studies are required to inform the utility of a more targeted strategy for these
therapeutic modalities in PPCI.
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Background: Compared to direct stenting (DS), balloon pre-dilatation (PD) may be
associated with increased vessel wall damage and particle embolization, which could
be associated with a higher rate of peri-procedural myocardial infarction (PPMI). We
aimed to compare the two interventional strategies in regards to the incidence of PPMI
among patients receiving elective percutaneous coronary intervention (PCI).
Methods: The study population was identified from a prospective registry of patients
undergoing PCI from 04/2003 to 12/2010. All patients with pre-procedural MI,
cardiogenic shock, in-stent restenosis, or rotational atherectomy were excluded from
analysis. The primary end point was the incidence of PPMI defined as an elevation of
creatinine kinase MB fraction levels to three times the upper limit of normal within
the first 24 hours after PCI. Additionally, major adverse cardiac events (MACE) at 1
year, as the composite of all-cause death, Q-wave MI and target lesion
revascularization, were also compared between patients undergoing DS vs. those
receiving PD. Propensity-score matching from a non-parsimonious logistic regression
model for treatment with DS vs. no DS was used to balance clinical and angiographic
characteristics of the two groups. 25 relevant clinical and angiographic variables were
used to calculate the propensity matching score. Patients receiving DS were matched
one-to-one to those receiving PD using the nearest available pair matching method.
Results: 493 patients were matched in each group. Mean age was 65 years and 67%
were male. The two groups were well matched. There were no significant clinical
differences between the two groups. Angiographic characteristics were similar except
for a higher number of lesions dilated in DS patients (1.46±1.24 vs. 1.27±0.61,
p=0.003). Patients with PD underwent longer procedures (p <0.001), and received
more contrast (p <0.001). PPMI did not differ between groups (4.3% DS vs. 6.3% PD,
p=0.159). No significant differences in 1-year MACE were observed (6.9% DS vs.
6.7%PD, p=0.899).
Conclusion: The incidence of PPMI during elective PCI is similar with PD or DS.
Unlike PCI for acute coronary syndrome, the strategy of direct stenting in the setting
of elective PCI has no effect on the incidence of PPMI.
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Background: ESC guidelines for the management of NSTE-ACS recommend an early
invasive strategy in high-risk patients. In clinical practice, only a minority of patients
are referred to an invasive strategy.
Methods: Between October 2006 to October 2008, 21,582 consecutive patients with
ACS were enrolled into the Euro-Heart-Survey ACS-Registry to document treatment
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